Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) with Prostate Cancer (CaP)

Inclusion Criteria

• GROUP 1 FOCUS GROUPS: * Individuals identifying as Black and male who are familiar with the landscape of medical care and cancer GROUP 1 SURVEYS: * Are 18 years of age or older * Have histologic evidence of prostate adenocarcinoma * Are requiring, have required, or will require prostate cancer treatment * Have an understanding of the protocol and its requirements * Are willing to fill in a questionnaire and participate in a focused interview * Are able and willing to sign an informed consent GROUP 1 INTERVIEWS: * Enrollment in the survey phase of the protocol GROUP 2: * Are 18 years of age or older * Are Black men or other discounted patients (older adults, individuals residing in rural or remote areas, and those facing transportation challenges) * Have histologic evidence of prostate adenocarcinoma * Are requiring active standard hormone-based therapies (degarelix or leuprolide), antibone resorptive agents (zoledronic acid or denosumab), oral anticancer treatments (abiraterone or second-generation androgen receptor blockers) or intravenous chemotherapy (docetaxel) * Are receiving part of supportive care/symptom management and/or anti-cancer therapy in the home as part of CCBW * Have an understanding of the protocol and its requirements * Are able and willing to sign informed consent

Exclusion Criteria

• GROUP 1 FOCUS GROUPS: * Individuals who do not identify as Black or male or who have had no extensive interaction with the healthcare system GROUP 1 SURVEYS: * Do not identify as Black men * Have not been diagnosed with prostate cancer GROUP 1 INTERVIEWS: * Not enrolled in the survey phase of the protocol GROUP 2: * Do not identify as Black men or other discounted patients (older adults, individuals residing in rural or remote areas, and those facing transportation challenges) * Have not been diagnosed with prostate cancer histologic evidence of prostate adenocarcinoma * Are not requiring active standard anti-cancer therapy